Keenova Therapeutics plc 8-K

What Happened
Keenova Therapeutics plc filed an 8-K on June 3, 2026 reporting the outcomes of its 2026 Annual General Meeting of Shareholders held June 2, 2026. All nine nominees were elected as directors to hold office until the 2027 AGM. PricewaterhouseCoopers LLP was re‑appointed as independent auditors and the Audit Committee was authorized to set auditor remuneration. Shareholders also approved an advisory vote on executive compensation (say-on-pay), selected annual frequency for future say-on-pay votes, approved a reduction of company capital (special resolution), and approved an amendment to the company’s articles (special resolution).

Key Details

• Director elections (votes FOR / AGAINST / ABSTAIN / BROKER NON-VOTES):
  • Paul M. Bisaro: 25,282,713 / 8,884 / 191,295 / 310,829
  • Leslie Donato: 25,291,597 / 0 / 191,295 / 310,829
  • Katina Dorton: 25,291,597 / 0 / 191,295 / 310,829
  • Paul Efron: 25,162,447 / 84,006 / 236,439 / 310,829
  • Scott Hirsch: 25,176,548 / 72,773 / 233,571 / 310,829
  • Sophia Langlois: 25,265,940 / 25,657 / 191,295 / 310,829
  • Sigurdur O. Olafsson: 25,285,209 / 6,388 / 191,295 / 310,829
  • Marc Yoskowitz: 25,272,285 / 19,312 / 191,295 / 310,829
  • Jonathan Zinman: 25,265,940 / 25,657 / 191,295 / 310,829
• Auditor re-appointment (Proposal 2): FOR 25,602,426; ABSTAIN 191,295; AGAINST 0; BROKER NON-VOTES 0.
• Say-on-pay (Proposal 3): FOR 24,965,301; AGAINST 326,296; ABSTAIN 191,295; BROKER NON-VOTES 310,829.
• Vote on frequency (Proposal 4): 1 year received 25,117,919 votes; company will hold annual advisory votes on executive pay going forward.
• Special resolutions: Reduction of capital (Proposal 5) approved FOR 25,256,218 / AGAINST 35,379; Amendment to articles (Proposal 6) approved FOR 25,476,547 / AGAINST 6,345.

Why It Matters
These results confirm board continuity and auditor continuity, both important for corporate oversight and financial reporting. Approval of the capital reduction and the articles amendment are material corporate actions that may enable future changes to the company’s capital structure or governance — investors should review the company’s proxy statement for details on the purpose and expected effects. The annual say-on-pay outcome and reappointment of PwC provide insight into shareholder support for management and the company’s financial controls.